» Articles » PMID: 30571380

Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction

Overview
Date 2018 Dec 21
PMID 30571380
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Background Because systemic inflammation and endothelial dysfunction lead to heart failure with preserved ejection fraction, we characterized plasma levels of inflammatory and cardiac remodeling biomarkers in patients with Fabry disease ( FD ). Methods and Results Plasma biomarkers were studied in multicenter cohorts of patients with FD (n=68) and healthy controls (n=40). Plasma levels of the following markers of inflammation and cardiac remodeling were determined: tumor necrosis factor ( TNF ), TNF receptor 1 ( TNFR 1) and 2 ( TNFR 2), interleukin-6, matrix metalloprotease-2 ( MMP -2), MMP -8, MMP -9, galectin-1, galectin-3, B-type natriuretic peptide ( BNP ), midregional pro-atrial natriuretic peptide ( MR -pro ANP ), and globotriaosylsphingosine. Clinical profile, cardiac magnetic resonance imaging, and echocardiogram were reviewed and correlated with biomarkers. Patients with FD had elevated plasma levels of BNP , MR -pro ANP , MMP -2, MMP -9, TNF , TNFR 1, TNFR 2, interleukin-6, galectin-1, globotriaosylsphingosine, and analogues. Plasma TNFR 2, TNF , interleukin-6, MMP -2, and globotriaosylsphingosine were elevated in FD patients with left ventricular hypertrophy, whereas diastolic dysfunction correlated with higher BNP , MR -pro ANP , and MMP -2 levels. Patients with late gadolinium enhancement on cardiac magnetic resonance imaging had greater levels of BNP , MR -pro ANP , TNFR 1, TNFR 2, and MMP -2. Plasma BNP , MR -pro ANP , MMP -2, MMP -8, TNF , TNFR 1, TNFR 2, galectin-1, and galectin-3 were elevated in patients with renal dysfunction. Patients undergoing enzyme replacement therapy who have more severe disease had higher MMP -2, TNF , TNFR 1, TNFR 2, and globotriaosylsphingosine analogue levels. Conclusions Inflammatory and cardiac remodeling biomarkers are elevated in FD patients and correlate with disease progression. These features are consistent with a phenotype dominated by heart failure with preserved ejection fraction and suggest a key pathogenic role of systemic inflammation in FD .

Citing Articles

Sex Differences in Circulating Inflammatory, Immune, and Tissue Growth Markers Associated with Fabry Disease-Related Cardiomyopathy.

Ivanova M, Dao J, Friedman A, Kasaci N, Goker-Alpan O Cells. 2025; 14(5).

PMID: 40072051 PMC: 11899294. DOI: 10.3390/cells14050322.


A systematic literature review to evaluate the cardiac and cerebrovascular outcomes of patients with Fabry disease treated with agalsidase Beta.

Oudit G, DasMahapatra P, Lyn N, Wilson F, Adeyemi A, Lee C Front Cardiovasc Med. 2025; 11:1415547.

PMID: 39906339 PMC: 11790562. DOI: 10.3389/fcvm.2024.1415547.


Incidence and Impact of Myocarditis in Genetic Cardiomyopathies: Inflammation as a Potential Therapeutic Target.

Lutokhina Y, Zaklyazminskaya E, Kogan E, Nartov A, Nartova V, Blagova O Genes (Basel). 2025; 16(1).

PMID: 39858598 PMC: 11765192. DOI: 10.3390/genes16010051.


Glycosphingolipids and their impact on platelet activity in a murine model of fabry disease.

Kanack A, Prodoehl E, Ishihara-Aoki M, Aoki K, Dahms N Sci Rep. 2024; 14(1):29488.

PMID: 39604471 PMC: 11603304. DOI: 10.1038/s41598-024-80633-6.


Complement System and Adhesion Molecule Skirmishes in Fabry Disease: Insights into Pathogenesis and Disease Mechanisms.

Magnusen A, Pandey M Int J Mol Sci. 2024; 25(22).

PMID: 39596318 PMC: 11594573. DOI: 10.3390/ijms252212252.


References
1.
Cheng-Baron J, Chow K, Khoo N, Esch B, Scott J, Haykowsky M . Measurements of changes in left ventricular volume, strain, and twist during isovolumic relaxation using MRI. Am J Physiol Heart Circ Physiol. 2010; 298(6):H1908-18. DOI: 10.1152/ajpheart.00131.2010. View

2.
Mehta A, Clarke J, Giugliani R, Elliott P, Linhart A, Beck M . Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet. 2009; 46(8):548-52. DOI: 10.1136/jmg.2008.065904. View

3.
Eng C, Niehaus D, Astrin K, Desnick R . Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease. Am J Hum Genet. 1993; 53(6):1186-97. PMC: 1682507. View

4.
Pries A, Badimon L, Bugiardini R, Camici P, Dorobantu M, Duncker D . Coronary vascular regulation, remodelling, and collateralization: mechanisms and clinical implications on behalf of the working group on coronary pathophysiology and microcirculation. Eur Heart J. 2015; 36(45):3134-46. DOI: 10.1093/eurheartj/ehv100. View

5.
Tajik A, Seward J, Hagler D, Mair D, Lie J . Two-dimensional real-time ultrasonic imaging of the heart and great vessels. Technique, image orientation, structure identification, and validation. Mayo Clin Proc. 1978; 53(5):271-303. View